Health Services, National
UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme
UK; drugmakers; medicine rebate; government negotiations; VPAG; statutory scheme; pharmaceutical industry; National Health Service; rebate rates
NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns
NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)